Critical Survey: Bumrungrad Hospital Public (OTC:BUHPF) vs. AirSculpt Technologies (NASDAQ:AIRS)

AirSculpt Technologies (NASDAQ:AIRSGet Free Report) and Bumrungrad Hospital Public (OTC:BUHPFGet Free Report) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for AirSculpt Technologies and Bumrungrad Hospital Public, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AirSculpt Technologies 0 5 0 0 2.00
Bumrungrad Hospital Public 0 0 0 0 N/A

AirSculpt Technologies currently has a consensus target price of $5.50, indicating a potential downside of 6.14%. Given AirSculpt Technologies’ higher possible upside, equities research analysts clearly believe AirSculpt Technologies is more favorable than Bumrungrad Hospital Public.

Institutional & Insider Ownership

91.5% of AirSculpt Technologies shares are owned by institutional investors. Comparatively, 8.3% of Bumrungrad Hospital Public shares are owned by institutional investors. 78.8% of AirSculpt Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares AirSculpt Technologies and Bumrungrad Hospital Public’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AirSculpt Technologies -1.77% 6.42% 2.63%
Bumrungrad Hospital Public N/A N/A N/A

Valuation & Earnings

This table compares AirSculpt Technologies and Bumrungrad Hospital Public”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AirSculpt Technologies $195.92 million 1.72 -$4.48 million ($0.07) -83.71
Bumrungrad Hospital Public N/A N/A N/A C$3.08 2.73

Bumrungrad Hospital Public has lower revenue, but higher earnings than AirSculpt Technologies. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Bumrungrad Hospital Public, indicating that it is currently the more affordable of the two stocks.

Summary

AirSculpt Technologies beats Bumrungrad Hospital Public on 6 of the 9 factors compared between the two stocks.

About AirSculpt Technologies

(Get Free Report)

AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips, or other areas. The company’s body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. It operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.

About Bumrungrad Hospital Public

(Get Free Report)

Bumrungrad Hospital Public Company Limited owns and operates healthcare-related entities in Thailand and internationally. It operates allergy, arrhythmia, behavioral health, breast, home service, heart valve, robotic surgery, rehabilitation, children’s, colorectal surgery, complex coronary artery intervention, cornea transplant, dental, diagnostic, dialysis, digestive disease, ear, nose, throat, emergency, endocrinology, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopedics, perinatal, plastic surgery, pulmonary, refractive surgery, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women’s centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, comprehensive sleep, IVF, hearing and balance, medical, memory, new life healthy aging, Parkinson’s disease and movement disorders, pride, surgery, vaccine clinics. In addition, it provides spine institute, diagnostic radiology and nuclear medicine, esperance, heart institute, intensive care unit, neurocritical care, nutrition services, pharmacy services, and preventive genomics and integrative medicine services. Further, the company offers clinical research; hospital consulting and management; healthcare personnel development and training; healthcare referral; and digital platform services. Additionally, it is involved in the distribution of pharmaceutical and medical goods in specialized stores; development of software for healthcare services; holding of real estate assets; and manufacture and sale of vitamin supplements. Bumrungrad Hospital Public Company Limited was founded in 1975 and is based in Bangkok, Thailand.

Receive News & Ratings for AirSculpt Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AirSculpt Technologies and related companies with MarketBeat.com's FREE daily email newsletter.